Latest News

Gossamer Bio Announces Data Presentation at the 2020 Crohn’s & Colitis Congress

SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that data from the Company’s Phase 1 multiple ascending dose study of GB004 in healthy volunteers have been accepted for presentation at the 2020 Crohn’s & Colitis Congress being held January 23- 25 in Austin, Texas. Details for th

Source link

Related posts

ADHD Meds No Help For Healthy Students’ Grades


No, there's still no link between video games and violence


What Do States Spend on Natural Disasters?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy